Kotak Life Sciences Fund I
Kotak Life Sciences Fund I is a healthcare-focused private-equity vehicle launched by Kotak Alternate Asset Managers in 2025. It targets early to growth-stage businesses across life sciences and healthcare, with public manager and company announcements confirming investments in Mediversal Healthcare and Zeroharm Sciences.
At a glance
- Founded
- 2025
- Footprint
- Mumbai
- Stage
- Early to growth-stage private equity across life sciences and healthcare
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Kotak Life Sciences Fund I uses a early to growth-stage private equity across life sciences and healthcare approach across Pharmaceuticals, medical devices, diagnostics, digital health.
Current evidence
Kotak Alternate Asset Managers announced a fund investment in Zeroharm Sciences in February 2026; the manager also announced a fund investment in Mediversal Healthcare in November 2025.
Strategy
Early to growth-stage private equity across life sciences and healthcare
Sector focus
Pharmaceuticals, medical devices, diagnostics, digital health
Current signal
Kotak Alternate Asset Managers announced a fund investment in Zeroharm Sciences in February 2026; the manager also announced a fund investment in Mediversal Healthcare in November 2025.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.